Tin tức & Cập nhật

Chỉ hiển thị Multimedia
Post-transplant KRd a new SoC for MM?

Post-transplant KRd a new SoC for MM?

07 Jul 2022 bởiAudrey Abella

In the ongoing phase III ATLAS study evaluating patients with newly diagnosed multiple myeloma (MM), progression-free survival (PFS) was better with maintenance treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) than lenalidomide (R) alone after autologous stem-cell transplantation (ASCT).

07 Jul 2022
Empagliflozin improves outcomes in HFpEF patients regardless of age

Empagliflozin improves outcomes in HFpEF patients regardless of age

06 Jul 2022 bởiStephen Padilla

Treatment with empagliflozin results in a reduction in heart failure (HF) risk and renal outcomes and in better health-related quality of life (HRQoL) among patients with chronic HF with preserved ejection fraction (HFpEF), a study has shown. In addition, the study drug is well tolerated by older patients.

06 Jul 2022